Biology and Treatment of Rhabdoid Tumor

Critical Reviews in Oncogenesis
James I GellerJaclyn A Biegel

Abstract

Rhabdoid tumor is a rare, highly aggressive malignancy that primarily affects infants and young children. These tumors typically arise in the brain and kidney, although extrarenal, non-central nervous system tumors in almost all soft-tissue sites have been described. SMARCB1 is a member of the SWI/SNF chromatin-remodeling complex and functions as a tumor suppressor in the vast majority of rhabdoid tumors. Patients with germline mutations or deletions affecting SMARCB1 are predisposed to the development of rhabdoid tumors, as well as the genetic disorder schwannomatosis. The current hypothesis is that rhabdoid tumors are driven by epigenetic dysregulation, as opposed to the alteration of a specific biologic pathway. The strategies for novel therapeutic approaches based on what is currently known about rhabdoid tumor biology are presented.

Citations

Mar 5, 2016·Journal of Clinical Pathology·Sangeetha N Kalimuthu, Runjan Chetty
Mar 25, 2017·The American Journal of Surgical Pathology·Satoshi NakataHideaki Yokoo
Nov 19, 2019·The Anatomical Record : Advances in Integrative Anatomy and Evolutionary Biology·Wai Chin Chong, Jason E Cain
Apr 17, 2020·Journal of Neuropathology and Experimental Neurology·Sanjib MukherjeeEkokobe Fonkem
Jun 10, 2020·Diagnostic Cytopathology·Saloni BansalAkash Pramod Sali
Nov 11, 2019·Virchows Archiv : an International Journal of Pathology·Sumihito NobusawaHideaki Yokoo
Dec 14, 2018·Frontiers in Oncology·Vivien ChanSumit Das
Sep 24, 2019·Frontiers in Medicine·Elizaveta Fasler-KanSteffen M Berger
Jul 12, 2017·Journal of Oncology Practice·Kathryn E BeckermannW Kimryn Rathmell
Jun 5, 2019·Cancer Research·Jing Huang, Ji Luo
Feb 16, 2021·Clinics in Perinatology·Sarah G MitchellChristopher C Porter
Nov 23, 2020·Journal of Cancer Research and Clinical Oncology·Yuichi ShibuiYoshinao Oda
Feb 16, 2021·Clinics in Perinatology·Sei-Gyung K Sze
Mar 12, 2021·Frontiers in Oncology·Giada Del BaldoAngela Mastronuzzi
May 14, 2021·The FEBS Journal·Marton Siklos, Stefan Kubicek
Jul 1, 2021·Cancer Management and Research·Jing LiDongsheng Huang
Jul 15, 2021·Advances in Radiation Oncology·Mariko KurokawaKatsuyuki Karasawa
Jun 27, 2021·ChemMedChem·Natalia MilosevichFraser Hof
Nov 14, 2020·Surgical Pathology Clinics·Amy L Treece
Sep 9, 2021·Medical Oncology·Mohadeseh ShayeghanMohammad Amin Javidi

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.